异基因造血干细胞移植后使用Eprenetapopt联合阿扎胞苷治疗TP53突变急性髓系白血病和骨髓增生异常综合征
这项多中心、开放标签的II期试验评估了Eprenetapopt联合阿扎胞苷作为TP53突变急性髓系白血病(AML)和骨髓增生异常综合征(MDS)患者异基因造血干细胞移植(HCT)后维持治疗的疗效与安全性。33例患者接受维持治疗,中位随访14.5个月时中位无复发生存期(RFS)为12.5个月(95%CI 9.6至不可估计),1年RFS概率为59.9%(95%CI 41至74);中位随访17.0个月时中位总生存期(OS)为20.6个月(95%CI 14.2至不可估计)。作者认为该维持方案耐受性良好,在高危人群中RFS和OS结果令人鼓舞。
要点
- 33例TP53突变AML或MDS患者接受HCT后Eprenetapopt联合阿扎胞苷维持治疗,中位年龄65岁。
- 中位RFS为12.5个月(95%CI 9.6至不可估计),1年RFS概率59.9%(95%CI 41至74)。
- 中位OS为20.6个月(95%CI 14.2至不可估计),1年OS概率78.8%(95%CI 60.6至89.3)。
核心结论
- 在TP53突变AML和MDS患者中,HCT后使用Eprenetapopt联合阿扎胞苷维持治疗耐受性良好,且在这一高危人群中RFS和OS结果令人鼓舞。
研究设计与样本
- 多中心、开放标签、II期临床试验(ClinicalTrials.gov标识:NCT03931291),评估Eprenetapopt联合阿扎胞苷作为HCT后维持治疗的疗效和安全性。
- 84例患者在HCT前接受资格筛查,55例接受了移植,最终33例(14例AML和19例MDS)接受维持治疗,中位年龄65岁(范围40-74岁)。
- 患者接受最多12个周期的Eprenetapopt 3.7 g每日一次静脉注射(第1-4天)联合阿扎胞苷36 mg/m2每日一次静脉/皮下注射(第1-5天),28天为一个周期。
主要发现
- Eprenetapopt的中位周期数为7(范围1-12)。
- 中位随访14.5个月时,中位RFS为12.5个月(95%CI 9.6至不可估计),1年RFS概率为59.9%(95%CI 41至74)。
- 中位随访17.0个月时,中位OS为20.6个月(95%CI 14.2至不可估计),1年OS概率为78.8%(95%CI 60.6至89.3)。
- 自首次给药起30天和60天死亡率分别为0%和6%(n=2)。
- 急性和慢性(所有级别)移植物抗宿主病不良事件发生率分别为12%(n=4)和33%(n=11)。
关键数值与推荐
- 主要结局为无复发生存期(RFS)和安全性。
- Eprenetapopt给药方案:3.7 g每日一次静脉注射,第1-4天。
- 阿扎胞苷给药方案:36 mg/m2每日一次静脉/皮下注射,第1-5天,28天为一周期,最多12个周期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Outcomes are poor in TP53-mutant (mTP53) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant (HCT). Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator. PATIENTS AND METHODS: We conducted a phase II, multicenter, open-label trial to assess efficacy and safety of eprenetapopt combined with azacitidine as maintenance therapy after HCT (ClinicalTrials.gov identifier: NCT03931291). Patients with mTP53 MDS or AML received up to 12 cycles of eprenetapopt 3.7 g once daily intravenously on days 1-4 and azacitidine 36 mg/m2 once daily intravenously/subcutaneously on days 1-5 in 28-day cycles. The primary outcomes were relapse-free survival (RFS) and safety. RESULTS: Of the 84 patients screened for eligibility before HCT, 55 received a transplant. Thirty-three patients ultimately received maintenance treatment (14 AML and 19 MDS); the median age was 65 (range, 40-74) years. The median number of eprenetapopt cycles was 7 (range, 1-12). With a median follow-up of 14.5 months, the median RFS was 12.5 months (95% CI, 9.6 to not estimable) and the 1-year RFS probability was 59.9% (95% CI, 41 to 74). With a median follow-up of 17.0 months, the median overall survival (OS) was 20.6 months (95% CI, 14.2 to not estimable) and the 1-year OS probability was 78.8% (95% CI, 60.6 to 89.3). Thirty-day and 60-day mortalities from the first dose were 0% and 6% (n = 2), respectively. Acute and chronic (all grade) graft-versus-host disease adverse events were reported in 12% (n = 4) and 33% (n = 11) of patients, respectively. CONCLUSION: In patients with mTP53 AML and MDS, post-HCT maintenance therapy with eprenetapopt combined with azacitidine was well tolerated. RFS and OS outcomes were encouraging in this high-risk population.
引用
- Mishra A, Tamari R, DeZern AE, et al. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2022. PMID: 35816664. doi:10.1200/JCO.22.00181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。